Product name :Rivaroxaban
CAS No: 366789-02-8
Molecular Formula: C19H18ClN3O5S
Appearance: white powder
Package: according to the clients requirement
Production Capacity: 500kg/month
Storage: Keep in cool, dry and sealed
Transportation: by sea or by air
Cutting shaaban and pekah ester group is currently the most promising two antithrombotic drugs, and the essential difference between traditional antithrombotic drug heparin is that it does not need antithrombin Ⅲ participation, free and can be directly antagonism Xa factor. Whereas heparin requires antithrombin Ⅲ can play a role, and prothrombin complex of Xa factor is invalid. These two new oral anticoagulants are hailed by the medical community as a major progress in the field of anticoagulant therapy and potential fatal thrombosis prevention, and will become a new milestone in the development history of cardiovascular drugs.
Rivaroxaban is also used to prevent venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee joint replacement. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation and reduce the risk of recurrence of coronary artery syndrome.